Drug Profile
CMV 423
Alternative Names: RPR CMV 423Latest Information Update: 25 Sep 2018
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antivirals; Indolizines; Pyridines; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cytomegalovirus infections; Human herpesvirus 6 infections
Most Recent Events
- 25 Sep 2018 Discontinued - Preclinical for Cytomegalovirus infections in France (unspecified route)
- 25 Sep 2018 Discontinued - Preclinical for Human herpesvirus-6 infections in France (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis